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Background:  Patients with severe, symptomatic aortic stenosis (AS) who do not undergo valve replacement surgery have a poor long-term 
prognosis. There are limited data, however, on the health resource consumption and medical costs during the final stages of the disease.
Methods:  Patients with severe symptomatic AS (hospitalized for heart failure) who did not undergo valve replacement surgery were identified in 
the 2003 Medicare 5% Standard Analytic Files and tracked over 5 years to measure clinical outcomes, medical resource use and costs.
Results:  We identified 2,150 patients with severe symptomatic AS who were managed medically. Mean age was 82 years, 64% were female, and 
mean EuroScore was 17% (30% with EuroScore >20%). Over 5-years of follow-up, overall mortality was 88.4% with mean survival duration of 1.8 
years. Over this time period, patients experienced an average of 4.4 inpatient hospitalizations and 52.0% were admitted to skilled nursing care. Total 
5-year costs were $63,844 per patient and averaged ~$20,000/year (see figure).
Conclusion: Elderly patients with severe aortic stenosis undergoing medical management have limited long-term survival but incur substantial 
costs to the Medicare Program. These results have important implications for policy makers interested in better understanding the cost-effectiveness 
of emerging treatment options such as transcatheter aortic valve replacement for patients with severe, symptomatic aortic stenosis who are 
currently managed medically. 
